Advanced Triple-Action Formula for Diabetes Control
GLIMIKO-MK GP2 Tablets by MK Healthcare are a high-potency, triple-drug combination designed for the aggressive management of Type 2 Diabetes Mellitus. This advanced formulation integrates Glimepiride (2mg), Metformin Hydrochloride (500mg) in a Sustained Release format, and Pioglitazone (15mg). It is specifically engineered for patients whose blood sugar levels are not adequately controlled by dual-therapy or single-agent medications. By targeting multiple metabolic pathways simultaneously, GLIMIKO-MK GP2 provides a comprehensive solution to achieve and maintain optimal glycemic targets.
Synergistic Glucose Regulation and Insulin Sensitivity
The clinical strength of GLIMIKO-MK GP2 lies in the unique synergy of its three active components. Glimepiride acts as a powerful sulfonylurea that stimulates the pancreas to release more insulin. Metformin works by suppressing glucose production in the liver and improving the body?s natural response to insulin. Finally, Pioglitazone serves as a potent insulin sensitizer, specifically targeting insulin resistance in muscle and fat tissues. Together, these ingredients ensure a significant reduction in both fasting and post-meal blood sugar levels, providing balanced, around-the-clock metabolic control.
Comprehensive Protection Against Diabetic Complications
Effective long-term management with GLIMIKO-MK GP2 is essential for safeguarding the body against the debilitating complications of chronic hyperglycemia. By maintaining stable HbA1c levels, this medication helps protect vital organ systems from microvascular and macrovascular damage. This includes reducing the risk of diabetic nephropathy (kidney failure), retinopathy (vision loss), and neuropathy (nerve damage). The inclusion of Sustained Release (SR) technology ensures that the medication is delivered gradually, minimizing side effects and providing a consistent therapeutic shield for your cardiovascular and renal health.
Pharmaceutical Excellence and Quality Assurance
Manufactured by MK Healthcare, an ISO-GMP certified leader in the pharmaceutical sector, GLIMIKO-MK GP2 is produced under the most stringent quality control protocols to ensure maximum safety and therapeutic efficacy. The tablets are packaged in premium ALU-ALU blister packs, which provide a superior barrier against moisture, light, and oxidation to maintain the stability of the sensitive active ingredients. As a trusted name in the cardio-diabetic sector, MK Healthcare provides professional-grade medications that empower patients to manage complex health conditions with confidence and lead a more vibrant life.
